Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Actuate Therapeutics IncNASDAQ: ACTU
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets rises 7.3% from a year ago
Other current assets stood at $385.44K at the end of Q1 FY2026, up 7.3% from a year earlier and down 20.4% from the prior quarter. Over 3 fiscal years it compounded at +143.0% a year.
Context
- Other current assets amounted to 4.3% of total assets at the end of Q1 FY2026, down 3.7 pp from a year earlier.
- Other current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +7.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $385.44K-20.4% QoQ
- Last fiscal yearDec 2025
- $484K+141934310850439776.0% YoY
- Year agoMar 2025
- $359.16K+7.3% since
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 484K USD
- Year-over-year change
- +141934310850439776.0%
- 3-year CAGR
- +143.0%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 484K | +141934310850439776.0% |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 36.91K | +9.4% |
| FY2022 | 2022-12-31 | 33.75K | — |
Other Current Assets vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +7.3% is the 2nd highest of 9, against a peer median of -20.1%.
- Other current assets amounts to 4.3% of total assets for ACTU, versus a peer median of 1.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $8.57M USD | -29.2% | — | 3.6% | |
| Mar 2026 | $3.76M USD | +3.1% | -36.7% | 1.0% | |
| Mar 2026 | $2.86M USD | +862.6% | -9.3% | 0.6% | |
| Mar 2026 | $1.97M USD | -39.7% | -16.3% | 1.3% | |
| Mar 2026 | CHF 1.84M CHF | -11.0% | — | 2.1% | |
| Mar 2026 | $1.77M USD | -37.8% | -37.7% | 1.5% | |
| Mar 2026 | $1.44M USD | -7.0% | -21.5% | 2.4% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $385.44K USD | +7.3% | +143.0% | 4.3% |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $162K USD | -79.7% | +26.6% | 0.7% |
| Peer median (excluding ACTU) | — | -20.1% | -18.9% | 1.4% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.